Perfromance Wealth Partners LLC Lowers Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Perfromance Wealth Partners LLC lessened its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 26.9% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 2,926 shares of the biotechnology company’s stock after selling 1,074 shares during the period. Perfromance Wealth Partners LLC’s holdings in Sarepta Therapeutics were worth $365,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. UMB Bank n.a. raised its holdings in shares of Sarepta Therapeutics by 105.9% in the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 197 shares during the period. Connective Portfolio Management LLC acquired a new position in Sarepta Therapeutics in the 3rd quarter valued at about $1,624,000. Handelsbanken Fonder AB grew its position in Sarepta Therapeutics by 12.3% in the 3rd quarter. Handelsbanken Fonder AB now owns 23,815 shares of the biotechnology company’s stock valued at $2,974,000 after acquiring an additional 2,600 shares in the last quarter. Centaurus Financial Inc. purchased a new stake in Sarepta Therapeutics during the second quarter worth about $221,000. Finally, Clearbridge Investments LLC boosted its stake in shares of Sarepta Therapeutics by 57.0% in the second quarter. Clearbridge Investments LLC now owns 237,354 shares of the biotechnology company’s stock valued at $37,502,000 after purchasing an additional 86,138 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on SRPT shares. Cantor Fitzgerald reiterated a “neutral” rating and set a $152.00 target price on shares of Sarepta Therapeutics in a report on Friday, September 20th. Leerink Partners increased their price objective on Sarepta Therapeutics from $165.00 to $230.00 and gave the company an “outperform” rating in a research note on Monday, June 24th. Bank of America boosted their target price on Sarepta Therapeutics from $166.00 to $213.00 and gave the stock a “buy” rating in a research note on Friday, June 21st. UBS Group upped their price target on Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Finally, BMO Capital Markets lifted their price objective on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research note on Monday, June 24th. Two analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $185.47.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock traded up $2.10 during mid-day trading on Friday, hitting $124.51. 868,402 shares of the stock were exchanged, compared to its average volume of 1,269,330. The stock’s fifty day simple moving average is $130.19 and its two-hundred day simple moving average is $132.46. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.90. Sarepta Therapeutics, Inc. has a 12-month low of $55.25 and a 12-month high of $173.25. The stock has a market capitalization of $11.77 billion, a price-to-earnings ratio of 1,131.91 and a beta of 0.82.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The firm had revenue of $362.90 million for the quarter, compared to the consensus estimate of $394.38 million. During the same quarter last year, the business posted ($0.27) EPS. The firm’s quarterly revenue was up 38.9% compared to the same quarter last year. On average, analysts forecast that Sarepta Therapeutics, Inc. will post 1.45 EPS for the current year.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Michael Andrew Chambers purchased 37,038 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the transaction, the director now directly owns 284,034 shares in the company, valued at $38,003,749.20. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Michael Andrew Chambers purchased 37,038 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The shares were bought at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the acquisition, the director now owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.